

Review on Study of A Novel Insulin Delivery Method for the Treatment of Diabetes

Yash Hadge¹, Nilesh Gorad², Rohit Auti³, Dipak Solanke⁴, Saurabh Sivse⁵

Department of Pharmacology

Samarth College of Pharmacy, Bangarwadi, Belhe, Pune, Maharashtra, India

yashhadge2001@gmail.com

Abstract: Diabetes consequences include both microvascular and macrovascular disease, which are both influenced by proper diabetes management. Because insulin injection therapy is difficult for many patients, novel methods of insulin delivery are of interest in the diabetes profession. This examination will discuss pulmonary insulin administration by inhalation. Since the 1920s, Lispro insulin has been used to treat diabetes mellitus nevertheless, regardless of a variety of formulations, exhaustive insulin treatment accompanying many regular injections has not been acquired by universal clinical approval. Inhaled insulin, on the other hand, appears to be a direct, well-tolerated, non-invasive alternative to subcutaneous routine insulin. Moreover, inhaled insulin has a more physiological insulin description than traditional insulin. Further studies are wanted to validate general efficacy and pulmonary security, to equate the various approaches, and to typify better their relative places in essence. As a result of the acknowledgment of the significance of closer control of glycemia and the increasing number of cases with type 2 diabetes the one enduring insulin, inhaled insulin keep enhancing progressively integral indiscriminate nudging diabetes..

Keywords: Diabetes Type 1, medication formulations, Drug delivery methods, insulin, portal system, nanoparticles, biodegradable polymers.

I. INTRODUCTION

Diabetes mellitus is a systemic, chronic, and progressive illness characterized by abnormalities in insulin, blood vessel structure, and function, as well as the metabolism of fat, carbohydrates, protein, and insulin. For the next 25 years, it is anticipated to rank among the world's major murderers and disablers. Due to a rise in sedentary lifestyles, the consumption of energy-rich diets, and obesity, there are already over 150 million diabetics globally, and by the year 2025, this figure is anticipated to reach 300 million or more. Chronic hyperglycemia and other abnormalities of the metabolism are features of the group of disorders known as diabetes mellitus, which have many aetiologies. Type I and type II diabetes, those brought on by certain processes or illnesses, as well as gestational diabetes, are all categorized according to their etiological causes. Diabetes mellitus type I is characterized by auto-immune lesions of pancreatic cells.¹

Diabetes mellitus (DM) It is a metabolic disorder form hyperglycemia, (fasting plasma glucose ≥ 126 mg/dL and/or 200 mg/dL 2 hours after 75 g oral glucose), glycosuria, hyperlipidaemia, negative nitrogen balance and sometimes ketonemia. A widespread pathological change is thickening of capillary basement membrane, increase in vessel wall matrix and cellular proliferation resulting in vascular complications like lumen narrowing, early atherosclerosis, sclerosis of glomerular capillaries, retinopathy, neuropathy, and peripheral vascular insufficiency.²

II. PATHOPHYSIOLOGY

Aetiology

Signs and symptoms of type 2 diabetes often develop slowly. In fact, you can be living with type 2 diabetes for years and not know it. When signs and symptoms are present, they may include:

Increased thirst

Frequent urination

Increased hunger

Copyright to IJAR SCT


www.ijarsct.co.in

DOI: 10.48175/IJAR SCT-9558



172

Unintended weight loss
 Fatigue
 Blurred vision
 Slow-healing sores
 Frequent infections
 Numbness or tingling in the hands or feet
 Areas of darkened skin, usually in the armpits and neck.⁷



Traditional insulin drug delivery system:

Insulin medicine via subcutaneous or new parenteral route in diabetic patient is preferred but on continuous administration there may be chance of peripheral hyperinsulinemia, formation of thrombus, inflammation & sensitivity at the site. also, patient pain from needle phobia hesitate to accept.

Historical education of easy insulin drug delivery system:

This science was first described in 19th century in France, when the company H Galante-manufactured an ‘Apparatus for Aqua puncture’. Since before, the demand had increases significantly. It was first commercialized in the US in 1960’s. Bio-jet had summed up the reason for it in their short declaring” Patients hate needles, healthcare specialists fear accidental needle stick injuries,drug companies are expecting new and innovative approaches of giving their products.⁶

Distinguish Between Type 1 & Type 2:

DIABETES MELLITUS	
TYPE 1 & TYPE 2	
Type 1 Diabetes	Type 2 Diabetes
<ul style="list-style-type: none"> ▪ Occurs when the Pancreas is unable to Produce enough Insulin ▪ Develop at a Young Age ▪ Cannot be prevented ▪ Require insulin therapy 	<ul style="list-style-type: none"> ▪ Occurs due to Insulin Resistance ▪ Develop at an Older age ▪ Can be prevented with lifestyle changes ▪ Can be managed with lifestyle modification alone if diagnosed early

Type 1

Diabetes affecting the young occurs when the pancreatic suspect containers stop generating insulin. Sweet liquid cannot list muscle containers for energy except that insulin is present. Instead, glucose levels in the blood rise, leading a person to become exceedingly ill. If insulin is recovered, type 1 diabetes can be lethal. Type 1 diabetics must inject and introduce insulin for the rest of their lives.

Insulin-dependent diabetes mellitus is most average in infants and bodies under the age of 30, but it can stand at some age.

This disorder is not made by a change in behaviour. Allure particular aetiology is obscure, but research displays that everything in the atmosphere can turn on it in one the one is genetically inclined it^{1,2}

In the nonobese diabetic murine model of insulin-dependent diabetes mellitus, daily extreme doses of insulin or the day-to-day government of an insulin analogue not leading to hypoglycemia supported 61% and 57% guardianship against diabetes individually.³

Type2

Type 2 diabetes occurs when the pancreas does not produce enough insulin and the insulin that is produced does not function properly (also known as insulin resistance). As a result, glucose levels in the blood begin to rise above normal. Because there are no symptoms, half of the persons with type 2 diabetes are unaware that they have the disease.

Type 2 diabetes affects 85 to 90 percent of all diabetics which cultivate type 2 diabetes are more given a classification member along the defect. Cause being outside and not the act of changing enough recreational activity increases the chance of having type 2 diabetes, it is considered a lifestyle condition.

Type 2 diabetes is distinguished by low insulin secretion and sensitivity. To achieve precise glucose control when controlling diabetes, daily subcutaneous injections of human insulin have historically been used. Although this method has improved glycaemic control, it is unable to entirely reproduce the natural, diurnal plasma profile of endogenous insulin. The discovery of innovative non-invasive insulin delivery methods promises to enhance diabetes care even further. The necessity for frequent insulin injections, anxiety that insulin injections will be unpleasant and difficult to give, and concerns about hypoglycemia and weight gain are just a few of the hurdles to starting insulin therapy.

1) Insulin is distributed in important-commonness pulses (every 5-15 summary) that are covered among more moderate, ultradian oscillations (each 80-12 minutes), Level of glucose in blood needle generally increases the size/bulk of secretory bursts 2) insulin pulses are produced in the doorway tone and sustain 40%- 80% first-pass hepatic origin, resulting in waveform dampening in the intrinsic distribution. The basic cause of hepatic insulin approval is the amplitude of insulin pulses. 3) Red body fluid insulin levels in the minor distribution are a criticism of birth control method production, classification, and mishap. 4-peptide is created in a bulk equimolar to insulin but is shabby more slowly. Five) Proinsulin and insulin are not hidden equimolarly, and proinsulin approval is inferior to that of insulin

because C-peptide, unlike insulin, is not removed by the liver suitable way, the discharge rate of C-peptide may be calculated from body tissue C-peptide levels. Flowing proinsulin makes up the middle from two points 10% and of rational fasting insulin, but possibly excessively raised in type 2 diabetes; nonetheless, very exact immunoassay methods are needed to equate undamaged proinsulin and the distinguishing and unspecific proinsulin products.

Originally explained in 1960, the authority of bovine insulin in Freund's supplementary experience to the inauguration of T bacterium-moderated insulinitis and diabetes. Insulin-caused IgE responses can have local, intrinsic, next, or postponed effects. An excellent but probably deadly fundamental exhibition of the Igi interfered response is generalized insulin sensitivity.²

Insulin antibodies, which delay and lower insulin performance, can also be caused in reaction to B- cell provocation accompanying animal-species in arrangements passed down more than 10 to 20 at another time, this reaction was observed once again accompanying these medications, insulin antibodies again caused lipoatrophy (opening 3-6 months following in position or time the start of insulin therapy) and were related to irregular IgM, IgG and IgA deposition. The obvious dispersion may be pushed by insulin antibodies Diabetes mellitus is a chronic, progressive, intrinsic disease characterized by the dysfunction of absorption of fat, carbohydrates, protein, insulin, function, and structure of ancestry vessels and imbalance. It is projected to become of the world's main disablers and murderers within the next 25 age. Currently, there are over 150 million diabetics in general and this number is likely to increase to 300 heap or more by old age 2025 due to an increase in sedentary behaviour, consumption of strength-rich diet, and obesity. Diabetes mellitus shows a group of diseases of heterogeneous study of animals, characterized by incessant hyperglycemia and other metabolic abnormalities.³

Insulin immunogenicity in diffusion is another potential issue, ahead IgG antibodies bridge the top tier and significance the potential to cause an unusual level of and oxygen in ancestry equilibrium in the fetus and youth. the unchanged backlash to insulin conceded the possibility of further producing advantageous accouterments. In the no-base diabetic rodent model of type 1 diabetes, daily management of insulin at extreme doses of management of circle insulin not provoking hypo-glycemia present 61% and 57% security against diabetes. All the approaches transfer insulin to the alveoli, chief to hasty incorporation of insulin had a connection with that visualized with insulin lispro but accompanying slightly more protracted event of operation. The biography-efficiency of inhaled insulin is nearly 10% accompanying the Exubera and AERx orders. Technosphere insulin pieces give the feeling of ultimate fast exhaustion, accompanying 30% to 45% bioactivity. The following subject cooperative of difference is almost 15% which is complementary to that visualized accompanying SC insulin. The most qualified inhaled insulin is Exubera, which has existed as the subject of state 3 dispassionate tests moved out up earlier in 1256 individualities following type 1 and type 2 diabetes. These studies have confirmed no disaster of glycaemic control and somewhat changeable changes in hypo-glycemia monotony, suggesting that insulin grant permission be produced through the alveoli in a fashion had connection with that of brisk-acting SC insulin in two together type land type 2 diabetes. The most-prepared inhaled insulin is Exubera, which has been the subject of phase 3 clinical tests transported out up until now in 1256 characters accompanying type 1 and type 2 diabetes. These studies have proved no misfortune of glycaemic control and kind of changeable changes in hypo-glycemia repetitiveness, suggesting that insulin maybe brought through the lungs in a fashion related to that of rapid-acting SC insulin in both type 1 and type 2 diabetes.⁴

Inhaled Insulin

A novel way to administer the medication insulin, which is used to treat diabetes, to the body was made available in the United States from September 2006 to October 2007. All of the currently available insulin formulations are administered by subcutaneous or intravenous injection after the only inhalable formulation was withdrawn.

The first such product to hit the market was called Exubera, which is a powdered form of recombinant human insulin that is inhaled into the lungs where it is absorbed. Following absorption, it starts to work within the body and continues for a few hours. Still required for diabetics is the injection of longer-acting basal insulin.⁵



Fig. Insulin Inhaler for Diabetes Treatment

Insulin Pen

An insulin injection system for the management of diabetes is called an insulin pen. A pen is made up of a "pen," a vial of insulin, and disposable pen needles.

Types:

Insulin pens are produced by a number of businesses, including Novo Nordisk, Aventis, and Eli Lilly. For the majority of their insulins, including NovoLog/Novo-Rapid, Humalog, and Lantus, these businesses manufacture pens.

Two pen systems exist:

1. The pen portion of a replaceable cartridge pen is reused. The vial is changed by inserting a new one once the insulin has been used up.
2. Prefilled pens are completely throwaway. The entire unit is thrown away once the insulin has been used up.⁵



Fig. Insulin Pen

Types of insulin


While intermediate or long-acting insulin helps with managing the body's overall needs, rapid- and short-acting insulin helps lower blood glucose levels after meals. Both supports controlling blood glucose levels.

Insulin does categorize established by means of how long its remnants adverb in the bulk. From fast to long-acting, efficient are five various types of insulin. While a few types of insulin occur clearly. The remainder of something is dense.

It is necessary to gently roll the pen or vial between your hands before injecting cloudy insulin to ensure it is mixed properly (until it looks milky). In the case of cloudy clear insulin, avoid using it.

The five types of insulin are:

1. Rapid-acting insulin
2. Short acting insulin
3. Intermediate acting insulin
4. Mixed insulin
5. Long-acting insulin



Type	Trade Name	Onset	Peak	Duration
Rapid	aspart glulisine lispro NovoRapid Apidra Humalog	10-15	1-1½ hr	3-5 hr
Short	Regular Humulin-R Novolin gr	30-45	2-3hr	6½ hr
Intermediate	NPH Humulin-N Novolin NPH	1-3hr	5-8hr	14-18 hr
Long	detemir glargine LEVEMIR Lantus	1-2 hr	8-10hr None	12-24 hr 22-24 hr

1. Rapid-acting insulin: Nearly 2.5 to 20 proceedings subsequently injection, fast-acting insulin starts to function. Individuals three hours afterward injection, appeal belongings are at their peak, and they can last for just before five hours. The risk of including a low level of glucose in the blood (level of glucose in the blood less than 4 mmol/L) is declined by this type of insulin, which acts more quickly following in position or time a portion of food and is related to the physique's natural insulin. Rapidly subsequently injecting this rather insulin, you must bite.
2. Regular insulin, also referred to as Novolin R or short-acting insulin, is a type of medication. It can be injected a little bit later than rapid-acting insulin in order to cover your insulin needs at mealtime.
3. Intermediate-acting: Insulin NPH so established as Humulin N or Novolin N. is an in-between-acting insulin made up of transparent metallic mineral insulin interrupted in the definitely charged polypeptide protamine NPH finishes more interminable than shorter-acting insulins, but not in the order that the later long-acting insulins.
4. Long-acting insulin: Tresiba is the lengthiest-acting insulin now on the market, and it doesn't appear that some remainder of something is in the works that would determine this event of effect. Tresiba comes through as a result of its extended (in addition to 40 hours) event of action and imperceptible variations in the drag's extraction levels it is given already regularly.⁴

III. METHODS

Details expressing the physiology of insulin mucus, benefits of pulsatile insulin distribution in diabetes subjects, effectiveness, and adverse or unwanted secondary effects of current normal insulin therapies for the administration of diabetes, conveniences, and difficulties of pancreas and land surrounded by the body of water transplantation, or

dispassionate tests are all examples of items that may be of interest. For qualitative reasoning, troubles including diabetes patients taking beat insulin healing or advanced IIT were contained. They were detached into the following categories: machine of insulin discharge in active Individuals and victims, current situations for diabetes, in the way that oral hypoglycaemic drugs, insulin remedy, organ meat, and islet transplantation, beat insulin healing.⁴

IV. RESULTS

According to our review of the available research, IIT helps diabetic ulcers, neuropathy, and nephropathy heal more quickly, decreases emergency room visits, and improves other diabetic conditions. In addition to increased insulin receptor expression, increased adipocyte insulin sensitivity is the most likely mechanism underlying this improvement.⁴

V. CONCLUSION

Needle-free technology has the obvious advantage of reducing patient anxiety about needle use. Other advantages include extremely fast injection compared to conventional needles and no needle disposal issues. Not only can it help the pharmaceutical industry increase product sales, but it also has the potential to improve compliance with dosage regimens and outcomes. Disease transmission through re-use of needles is a major issue in the developing world. Organizations such as the World Health Organization and the centres for Disease Control, as well as charitable organisations such as the Gates Foundation, have advocated for the development of needle-free drug delivery methods.⁵

REFERENCES

- [1]. Essential of Medical Pharmacology , Jaypee Production, K.D. Tripathi , Volume 8th edition (2013), 276-294.
- [2]. Overview of novel routes of Insulin : Current Status, Lopamudra roy, International Journal of Advances in Medicine · October 2020.
- [3]. Diabetes fact sheet no.312 : World Health Organization ;2013 ,
- [4]. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type 1 diabetes in prediabetic NOD mice. J Clin Invest. 1997;100:1344-1348.
- [5]. Fry A. Insulin delivery device technology 2012: where are we after 90 years ? J Diabetes sci Techno 2012;6;947-53.
- [6]. Journal of emerging technologies and innovative research (JETIR) , Novel routes of insulin for diabetes treatment, S.G. Nagargoje , A.A. Muchandi.
- [7]. Skyler J. Pulmonary inhaled insulin: an overview and prediction for the future. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
- [8]. Ricordi C. Lilly Lecture: Islet transplantation: a brave new world. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association; June 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
- [9]. Karounos D. Immune response to insulin: Implications for alternative route insulin therapy. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association; September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
- [10]. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type 1 diabetes in prediabetic NOD mice. J Clin Invest. 1997;100:1344-1348.
- [11]. Diabetes Prevention Trial -- Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685-1691.
- [12]. Smaldone GC. Concepts of aerosol therapy for the modern clinician. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
- [13]. Skyler J. Pulmonary inhaled insulin: an overview and prediction for the future. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.

- [14]. Kapitza C, Hompesch M, Thompsen LK, Heise T. Intra-subject variability of pulmonary insulin via the AERx insulin diabetes management system versus subcutaneous insulin. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 417-P. Diabetes, Volume 51, Supplement 2.
- [15]. Rosenstock J, for the Exubera Phase III Study Group. Mealtime rapid-acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral agents: 3 month, randomized, comparative trial. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 535-P. Diabetes, Volume 51, Supplement 2.
- [16]. Modi P, Yutzy P, Klein K, Levin P. Oral insulin increases post-prandial insulin peaks and improves glucose control in type 2 diabetic patients. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 440-P. Diabetes, Volume 51, Supplement 2.
- [17]. Smith AM, Woods TJ, Williams DJ, et al. Transdermal basal insulin delivery through microspheres. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Abstract 191-OR. Diabetes, Volume 51, Supplement 2.
- [18]. Saudek CD. Update on implantable pumps. In: Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement
- [19]. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. *N Engl J Med.* 1989;321:574-579.
- [20]. Walter H. Insulin delivery by implanted pumps: one-year trial with programmable infusion systems (the Point Study). *Int J Artif Organs.* 1989;12:793-798.
- [21]. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG. Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. *Diabetes Care.* 1997;20:59-63.
- [22]. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. *Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care.* 1995;18:388-392.
- [23]. Saudek CD, Duckworth WC, Giobbie-Hurder A, et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. *JAMA.* 1996;276:1322-1327.
- [24]. L Heinemann. "Overcoming obstacles: new management options", *European Journal of Endocrinology*, 2004
- [25]. Elena Matteucci, Ottavio Giampietro, Vera Covolan, Daniela Giustarini, Paolo Fanti, Ranieri Rossi. "Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) <1% delivery", *Drug Design, Development and Therapy*, 2015
- [26]. Eman Mahmoud Shaaban, Doha Elsayed Ellakwa, Nesma Mohamed Elaraby, Khalda Sayed Amr, Ahmed Mahmoud Mohamad. "The effect of insulin-loaded gold and carboxymethyl chitosan nanoparticles on gene expression of glucokinase and pyruvate kinase in rats with diabetes type 1", *Journal of Food Biochemistry*, 2022
- [27]. <https://www.pharmatutor.org/articles/recent-trends-in-insulin-drug-delivery-system>
- [28]. <https://www.medscape.org/viewarticle/438371>
- [29]. <https://healthhearty.com/pathophysiology-of-diabetes-mellitus#:~:text=The%20pathophysiology%20of%20Type%201%20diabetes%20mellitus%20suggests,Consequently%2C%20the%20pancreas%20secretes%20little%20or%20no%20insulin>
- [30]. [https://www.endo.theclinic.com/article/S08898529\(13\)00037-6](https://www.endo.theclinic.com/article/S08898529(13)00037-6).
- [31]. <https://pdfcookie.com/>
- [32]. <https://www.ijmedicine.com/index.php/ijam>
- [33]. <https://diabetestalk.net/>